Physician profile
Wanda E Figueroa
NPI 1194811463
$14,144.71
in general payments reported to CMS, 2019-2025
16 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,489 · 2020: $348 · 2021: $538 · 2022: $738 · 2023: $950 · 2024: $2,512 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,999 · Travel and Lodging: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,999.08 |
| Travel and Lodging | $1,032.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $8,674.36 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Janssen Products, LP | $2,332.90 | 2019-2022 | |
| Gilead Sciences, INC. | $1,512.31 | 2019-2025 | Biktarvy, Descovy, Sunlenca |
| Merck Sharp & Dohme LLC | $551.40 | 2019-2025 | Pifeltro, Delstrigo, Isentress |
| Janssen Biotech, INC. | $509.84 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $253.22 | 2019-2025 | Serostim |
| Theratechnologies INC. | $136.35 | 2020-2024 | Trogarzo, Egrifta Sv, Egrifta |
| Napo Pharmaceuticals INC | $31.63 | 2019-2024 | Mytesi |
| Abbvie INC. | $29.06 | 2023 | |
| Hologic Sales and Service, LLC | $20.37 | 2025 | Aptima |
| Otsuka America Pharmaceutical, INC. | $18.30 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $16.94 | 2023 | Bexsero |
| Neurocrine Biosciences, INC. | $15.94 | 2023 | Ingrezza |
| Amag Pharmaceuticals, INC. | $14.69 | 2019 | |
| Pfizer INC. | $14.29 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $13.11 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.